Proneurotensin/neuromedin N secreted from small cell lung carcinoma cell lines as a potential tumor marker
暂无分享,去创建一个
[1] R. Dwek,et al. Proteome analysis of a human uveal melanoma primary cell culture by 2‐DE and MS , 2005, Proteomics.
[2] Tomoko Umaki,et al. Possible detection of pancreatic cancer by plasma protein profiling. , 2005, Cancer research.
[3] J. Carmody,et al. Mass profiling‐directed isolation and identification of a stage‐specific serologic protein biomarker of advanced prostate cancer , 2005, Proteomics.
[4] T. Colgan,et al. A strategy for high‐resolution protein identification in surface‐enhanced laser desorption/ionization mass spectrometry: Calgranulin A and chaperonin 10 as protein markers for endometrial carcinoma , 2005, Proteomics.
[5] T. Colgan,et al. Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. , 2005, Journal of proteome research.
[6] G. Bepler,et al. Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. , 2004, Lung cancer.
[7] D. Dillon,et al. 2D LC/MS analysis of membrane proteins from breast cancer cell lines MCF7 and BT474. , 2004, Journal of proteome research.
[8] Donald R Schwartz,et al. Comprehensive proteome analysis of ovarian cancers using liquid phase separation, mass mapping and tandem mass spectrometry: A strategy for identification of candidate cancer biomarkers , 2004, Proteomics.
[9] F. Miller,et al. A two‐dimensional liquid‐phase separation method coupled with mass spectrometry for proteomic studies of breast cancer and biomarker identification , 2004, Proteomics.
[10] Yu Shyr,et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer , 2003, The Lancet.
[11] Michael J Campa,et al. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. , 2003, Cancer research.
[12] M. Oka,et al. Peptidomics-based approach reveals the secretion of the 29-residue COOH-terminal fragment of the putative tumor suppressor protein DMBT1 from pancreatic adenocarcinoma cell lines. , 2002, Cancer research.
[13] P. Kitabgi,et al. Production of recombinant large proneurotensin/neuromedin N-derived peptides and characterization of their binding and biological activity. , 2002, Biochemical and biophysical research communications.
[14] Y. Akiyama,et al. Mass spectrometric high-throughput analysis of serum-free conditioned medium from cancer cell lines. , 2001, Cancer letters.
[15] J. Laissue,et al. Neurotensin receptors in human neoplasms: High incidence in Ewing's sarcomas , 1999, International journal of cancer.
[16] H. Dienemann,et al. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas. , 1999, Anticancer research.
[17] R. Carraway,et al. Neurotensin receptor expression in prostate cancer cell line and growth effect of NT at physiological concentrations , 1997, The Prostate.
[18] B. Evers,et al. Inhibition of neurotensin‐induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692 , 1997, Cancer.
[19] R. Kiss,et al. Neurotensin-mediated effects on astrocytic tumor cell proliferation , 1996, Neuropeptides.
[20] E. Daniel,et al. Role of endopeptidase 3.4.24.16 in the catabolism of neurotensin, in vivo, in the vascularly perfused dog ileum , 1994, British journal of pharmacology.
[21] K. Yamaguchi,et al. Pro-gastrin-releasing peptide(31-98) is a specific tumor marker in patients with small cell lung carcinoma. , 1994, Cancer research.
[22] T. Davis,et al. Neurotensin may function as a regulatory peptide in small cell lung cancer , 1991, Peptides.
[23] S. McNeil,et al. The rat gene encoding neurotensin and neuromedin N. Structure, tissue-specific expression, and evolution of exon sequences. , 1988, The Journal of biological chemistry.
[24] F. Checler,et al. Neuromedin N: high affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases. , 1986, European journal of pharmacology.
[25] P. Kitabgi,et al. Neurotensin-mediated inhibition of cyclic AMP formation in neuroblastoma N1E115 cells: involvement of the inhibitory GTP-binding component of adenylate cyclase. , 1986, Molecular pharmacology.
[26] J. Fahrenkrug,et al. Neurotensin-like immunoreactivities in human plasma: Feeding responses and metabolism , 1986, Peptides.
[27] C. Pert,et al. High levels of intracellular bombesin characterize human small-cell lung carcinoma. , 1981, Science.
[28] Gabriela Alexe,et al. A robust meta‐classification strategy for cancer detection from MS data , 2006, Proteomics.
[29] John D. Minna,et al. Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer , 1985, Nature.